Skip to content

Ionis Pharmaceuticals IONS Increase (Decrease) in Other Operating Assets

Increase (Decrease) in Other Operating Assets at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
-$349M-126%
Pfizer logo
PfizerPFE
BridgeBio Pharma logo
BridgeBio PharmaBBIO
Amgen logo
AmgenAMGN

Other financials

Income statement

See full
Revenue$246.1M+87.0%
Gross profit$243.1M+86.8%
Operating income-$117.4M+20.0%
Net income-$92.5M+37.0%
EPS (diluted)-$0.56+39.8%

Balance sheet

See full
Cash & equivalents$173.4M-34.4%
Total debt$691.7M+334%
Total equity$491.4M+3.3%
Total assets$3.4B+22.6%

Cash flow

See full
Operating cash flow-$792.8M-426%
CapEx$21.8M+73.0%
Free cash flow-$814.6M-399%

Valuation

See full
Market cap$12.25B+159%
Enterprise value$12.77B+175%
P/S11.6×+5.0×

Profitability

See full
Gross margin98.4%-0.2pp
Operating margin-33.3%-11.0pp
Net margin-30.9%-10.5pp
FCF margin-77.4%+35.3pp

Returns & leverage

See full
Return on equity-67.6%-20.3pp
Debt / equity1.4×+1.1×
Current ratio4.1×-5.6×

Where this comes from

Reported directly by Ionis Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherOperatingAssets.

The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ionis Pharmaceuticals's increase (decrease) in other operating assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ionis Pharmaceuticals's increase (decrease) in other operating assets?
Ionis Pharmaceuticals (IONS) reported increase (decrease) in other operating assets of $7.39M in Q1 2026.
How has Ionis Pharmaceuticals's increase (decrease) in other operating assets changed year-over-year?
Ionis Pharmaceuticals's increase (decrease) in other operating assets decreased by 40.2% year-over-year, from $12.37M to $7.39M.
What is the long-term trend for Ionis Pharmaceuticals's increase (decrease) in other operating assets?
Over 2 years (2021 to 2024), Ionis Pharmaceuticals's increase (decrease) in other operating assets has grown at a 455.7% compound annual growth rate (CAGR), from $877K to $27.08M.